Formulation design and optimization of orodispersible tablets of etoricoxib by response surface methodology

Main Article Content

S R Shahi
G R Agrawal
N V Shinde
S A Shaikh
S S Shaikh
A N Padalkar
V G Somani

Abstract

The purpose of the present investigation was to design a formulation of orodispersible tablets of Etoricoxib by adopting a systematic approach of 32 factorial design and to evaluate various quality control parameters. Etoricoxib is a novel, selective second-generation cyclooxygenase-2 inhibitor administered orally as an analgesic and antiinflammatory drug that is used for the treatment of osteoarthritis, rheumatoid arthritis and gouty arthritis. The poor aqueous solubility of the drug leads to variable dissolution rates. In the present investigation, an attempt has been made to prepare orodispersible tablets of Etoricoxib using three different directly compressible fillers to improve mouthfeel with an enhanced dissolution rate. In the study, a 32 full factorial design was adopted to investigate the joint influence of two formulation variables: amount of mannitol and crospovidone and the evaluation thereof. Response surface plots were also presented to represent graphically the effect of the independent variables on the disintegration time and drug percent dissolved in 60 s. The statistical model
is mathematically valid as the experimental (actual) values and predicted values suggested by the full model were relatively close to each other. This systematic formulation approach will help in understanding the effect of formulation variables
and permits the arbitrary selection of a batch of tablets with improved dissolution profile after oral administration of the
selective COX-2 inhibitor.

Downloads

Download data is not yet available.

Article Details

How to Cite
Shahi, S. R., Agrawal, G. R., Shinde, N. V., Shaikh, S. A., Shaikh, S. S., Padalkar, A. N., & Somani, V. G. (2014). Formulation design and optimization of orodispersible tablets of etoricoxib by response surface methodology. Asian Journal of Pharmaceutics (AJP), 3(2). https://doi.org/10.22377/ajp.v3i2.250
Section
Articles

References

European Pharmacopoeia 5.0, Council of Europe, Strasbourg codex,

France (1) 2005, 628.

Gohel M, Patel M, Amin Am, Agrawal R, Dave R, Bariya N. Formulation

design and optimization of mouth dissolve tablets of nimesulide using

vacuum drying technique. AAPS PharmSciTech 2004;5:e36.

de Waard H, Hinrichs WL, Visser MR, Bologna C, Frijlink HW. Unexpected

differences in dissolution behavior of tablets prepared from solid

dispersions with a surfactant physically mixed or incorporated. Int J

Pharm 2008;349:66-73.

Vijaya KS, Mishra DN. Rapidly disintegrating oral tablets of meloxicam.

Indian Drugs 2006;43:117-21.

Lachman L, Lieberman HA, Kanig JL. The theory and practice of

industrial pharmacy. 3rd ed. Bombay: Varghese Publishing House; 1987.

p. 66- 9,171-197, 293-345.

Indian Pharmacopoeia. Delhi Published by the Controller of

Publications; 1996. p. 734-6, A-80-A84.

Chaudhari PD, Chaudhari SP, Lanke SD. Formulation and in vitro

evaluation of taste masked orodispersible dosage form of levocetrizine

dihydrochloride. Indian Journal of Pharmaceutical Education and

Research 2007;41:319-28.

Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J

Pharm Sci 2002;15:295-305.

Fda.gov. Available from: Http://fda.gov. [last accessed on 2008 Jan 16].

Immediate Release Scale-up and Post Approval Change (SUPAC) Expert

Working Group of the Chemistry Manufacturing Controls Coordinating

Committee (CMC CC) of the Center for Drug Evaluation and Research.

Zhao N. Investigation of Superdisintegrant Functionality and

Development of Discriminating Test Methods [dissertation]. Baltimore,

MD: University of Maryland; 2005.

Most read articles by the same author(s)